Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147599 | 0.74 | NPC1 (0.50) | SMN1; SMN2PRMT5HPGD | |
| SCHEMBL30882479 | 0.70 | HPGDS (0.49) | SMN1; SMN2PRMT5LMNAHPGD | |
| SCHEMBL1194458 | 0.68 | NPC1 (0.59) | SMN1; SMN2PRMT5LMNAHPGD | |
| SCHEMBL2850367 | 0.68 | ALKBH2 (0.72) | HPGD | |
| SCHEMBL3916180 | 0.67 | MAP4K4 (0.55) | SMN1; SMN2PRMT5HPGD | |
| SCHEMBL30882345 | 0.67 | HPGDS (0.51) | SMN1; SMN2PRMT5KLKB1HPGD | |
| SCHEMBL23354814 | 0.65 | ADAMTS7 (0.54) | SMN1; SMN2PRMT5 | |
| SCHEMBL30882559 | 0.65 | PRMT5 (0.47) | SMN1; SMN2PRMT5HPGD | |
| SCHEMBL2605693 | 0.65 | HPGDS (0.62) | SMN1; SMN2PRMT5MAPK8HPGD | |
| SCHEMBL19542355 | 0.64 | PRMT5 (0.74) | SMN1; SMN2PRMT5MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787619-B1 | SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES | SCUOLA INT SUPERIORE DI STUDI AVANZATI SISSA (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-20210093626-A1 | SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-04-01 | — | — | US | disclosed |
| US-20210093626-A1 | SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093626-A1 | SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES | PRNP, SERPINA3, SERPINE1 | SMN1; SMN2 118/4885PRMT5 2908/4885P2RX7 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.